Q1 2025 · 13F-HR
BML Capital Management, LLCholdings as filed
Filed 2025-05-07 · accession 0001754960-25-000280
$123.6M
Reported value
27
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $22.8M | 18.4% | 7,609,812 | Common | NONE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $21.8M | 17.6% | 14,250,000 | Common | NONE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $13.3M | 10.7% | 3,824,417 | Common | NONE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $12.0M | 9.70% | 2,742,317 | Common | NONE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $7.8M | 6.33% | 5,749,432 | Common | NONE |
| 45783C200 | TIL | INSTIL BIO INC | $7.2M | 5.85% | 416,720 | Common | NONE |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $6.7M | 5.40% | 4,221,546 | Common | NONE |
| 68403P203 | ORMP | ORAMED PHARMACEUTICALS INC | $6.5M | 5.23% | 3,020,748 | Common | NONE |
| 45175G108 | — | IKENA ONCOLOGY INC | $4.7M | 3.84% | 3,710,803 | Common | NONE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $4.1M | 3.31% | 3,747,612 | Common | NONE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $3.4M | 2.72% | 1,890,245 | Common | NONE |
| N51517105 | 4PKB | LAVA THERAPEUTICS NV | $2.5M | 2.02% | 1,960,610 | Common | NONE |
| 49372L209 | 2KZ0 | KEZAR LIFE SCIENCES INC | $2.0M | 1.61% | 408,138 | Common | NONE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $1.5M | 1.24% | 5,890,934 | Common | NONE |
| 046484309 | ASTC | ASTROTECH CORP | $1.4M | 1.16% | 220,410 | Common | NONE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $1.2M | 0.93% | 2,093,232 | Common | NONE |
| 78667J108 | SG7 | SAGE THERAPEUTICS INC | $1.1M | 0.87% | 135,095 | Common | NONE |
| 04746L104 | — | ATHIRA PHARMA INC | $911,870 | 0.74% | 3,200,667 | Common | NONE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $908,986 | 0.74% | 1,136,091 | Common | NONE |
| 128058302 | LSTA | LISATA THERAPEUTICS INC | $509,605 | 0.41% | 216,853 | Common | NONE |
| 90042W100 | — | TURNSTONE BIOLOGICS CORP | $452,388 | 0.37% | 1,103,386 | Common | NONE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $375,000 | 0.30% | 150,000 | Common | NONE |
| 022307102 | ALMS | ALUMIS INC | $304,710 | 0.25% | 49,627 | Common | NONE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $131,379 | 0.11% | 273,536 | Common | NONE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $77,231 | 0.06% | 174,651 | Common | NONE |
| 43157M102 | — | HILLEVAX INC | $30,102 | 0.02% | 20,760 | Common | NONE |
| 00449L102 | 698 | ACHILLES THERAPEUTICS PLC | $0 | — | 3,804,921 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.